126 related articles for article (PubMed ID: 24873792)
21. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.
Chen L; Li F; Zhuang H; Jing H; Du Y; Zeng Z
J Nucl Med; 2009 Mar; 50(3):397-400. PubMed ID: 19223405
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
23. [New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma].
Czepczyński R; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J
Pol Arch Med Wewn; 2006 Sep; 116(3):853-60. PubMed ID: 18652278
[TBL] [Abstract][Full Text] [Related]
24. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
25. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan.
Jing H; Li F; Zhuang H; Wang Z; Tian J; Xing X; Jin J; Zhong D; Zhang J
Eur J Radiol; 2013 Nov; 82(11):2028-34. PubMed ID: 23721625
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
[TBL] [Abstract][Full Text] [Related]
27. Tc-99m depreotide imaging of I-131-negative recurrent metastatic papillary thyroid carcinoma.
Valsamaki P; Gotzamani-Psarrakou A; Tsiouris S; Molyvda-Athanasopoulou E; Psarrakos K; Papantoniou V; Gerali S; Zerva C
Int J Cancer; 2006 Aug; 119(4):968-70. PubMed ID: 16550594
[TBL] [Abstract][Full Text] [Related]
28. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
29. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
[TBL] [Abstract][Full Text] [Related]
30. 99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer.
Rodrigues M; Li S; Gabriel M; Heute D; Greifeneder M; Virgolini I
J Clin Endocrinol Metab; 2006 Oct; 91(10):3997-4000. PubMed ID: 16895961
[TBL] [Abstract][Full Text] [Related]
31. Technetium-99m tetrofosmin uptake in insular thyroid carcinoma. A comparison with iodine-131.
Degirmenci B; Aydin A; Comlekci A; Ozdogan O; Bekis R
Clin Nucl Med; 2003 May; 28(5):385-8. PubMed ID: 12702934
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of
Chen H; Li Y; Gao X; Shen X
Clin Imaging; 2018; 52():365-369. PubMed ID: 30248495
[TBL] [Abstract][Full Text] [Related]
33. 99mTc-EDDA/HYNIC-TOC in management of patients with head and neck somatostatin receptor positive tumors.
Trogrlic M; Tezak S
Nucl Med Rev Cent East Eur; 2016; 19(2):74-80. PubMed ID: 27479884
[TBL] [Abstract][Full Text] [Related]
34. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid.
Christian JA; Cook GJ; Harmer C
Br J Cancer; 2003 Jul; 89(2):258-61. PubMed ID: 12865913
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.
Fujie S; Okumura Y; Sato S; Akaki S; Katsui K; Himei K; Takemoto M; Kanazawa S
Acta Med Okayama; 2005 Jun; 59(3):99-107. PubMed ID: 16049563
[TBL] [Abstract][Full Text] [Related]
36. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
37. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
38. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
[TBL] [Abstract][Full Text] [Related]
39. Clinical indications to the use of (99m)Tc-EDDA/HYNIC-TOC to detect somatostatin receptor-positive neuroendocrine tumors.
Parisella MG; Chianelli M; D'Alessandria C; Todino V; Mikolajczak R; Papini E; Dierckx RA; Scopinaro F; Signore A
Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):90-8. PubMed ID: 21068709
[TBL] [Abstract][Full Text] [Related]
40. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy.
Morris JC; Kim CK; Padilla ML; Mechanick JI
Thyroid; 1997 Feb; 7(1):63-6. PubMed ID: 9086573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]